Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine

Tal Patalon; Yaki Saciuk; Asaf Peretz; Galit Perez; Yoav Lurie; Yasmin Maor; Sivan Gazit

doi:10.1038/s41467-022-30884-6

Nature Communications (Jun 2022)

Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine

Tal Patalon,
Yaki Saciuk,
Asaf Peretz,
Galit Perez,
Yoav Lurie,
Yasmin Maor,
Sivan Gazit

Affiliations

Tal Patalon: Kahn Sagol Maccabi (KSM) Research & Innovation Center, Maccabi Healthcare Services
Yaki Saciuk: Kahn Sagol Maccabi (KSM) Research & Innovation Center, Maccabi Healthcare Services
Asaf Peretz: Maccabitech Institute for Research and Innovation, Maccabi Healthcare Services
Galit Perez: Maccabitech Institute for Research and Innovation, Maccabi Healthcare Services
Yoav Lurie: Liver unit, Shaare Zedek City Center Campus
Yasmin Maor: Faculty of Medicine, Tel Aviv University
Sivan Gazit: Kahn Sagol Maccabi (KSM) Research & Innovation Center, Maccabi Healthcare Services

DOI: https://doi.org/10.1038/s41467-022-30884-6
Journal volume & issue: Vol. 13, no. 1
pp. 1 – 7

Abstract

Read online

In this retrospective study, authors show that relative protection against SARS-CoV-2 infection wanes from 53.4% one month after vaccination to 16.5% three months after vaccination, suggesting that there is a significant waning of mRNA vaccine effectiveness against infection with the Omicron variant.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal